Activating mutations of K-ras are the most common oncogenic alterations found in lung
cancer. Unfortunately, attempts to target K-ras–mutant lung tumors have thus far failed …

Oncogenic KRAS mutations occur frequently in lung adenocarcinoma. The signaling
pathways activated by IL6 promote Kras-driven lung tumorigenesis, but the basis for this …

Somatic KRAS mutations are the most common oncogenic variants in lung cancer and are
associated with poor prognosis. Using a Kras-induced lung cancer mouse model, CC-LR …

Recent studies suggest that high expression of the proinflammatory cytokine IL6 is
associated with poor survival of lung cancer patients. Accordingly, IL6 has been a target of …

Cancer cells that succeed in forming metastasis need to be reprogrammed to evade immune
surveillance and survive in a new microenvironment. This is facilitated by metastatic niches …

K-Ras–induced lung cancer is a very common disease, for which there are currently no
effective therapies. Because therapy directly targeting the activity of oncogenic Ras has …

K-ras–mutant lung adenocarcinoma (KM-LUAD) is associated with abysmal prognosis and
is tightly linked to tumor-promoting inflammation. A human mAb, canakinumab, targeting the …

Lung adenocarcinomas (LUADs) with mutations in the K-ras oncogene display dismal
prognosis. Proinflammatory and immunomodulatory events that drive development of K-ras …

Background Conditional transgenic models have established that tumors require sustained
oncogene activation for tumor maintenance, exhibiting the phenomenon known as …

Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based
targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma …